Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China

Conclusion: The results suggest that dual therapy of LPV/r plus 3TC is non-inferior to the first-line triple-therapy regimen in China.

http://www.ijmm.org/text.asp?2018/36/4/513/254385

Source: Indian Journal of Medical Microbiology - March 17, 2019 Category: Microbiology Authors: Linghua Li Haolan He Yun Lan Jinfeng Chen Huolin Zhong Jingmin Nie Xiejie Chen Fengyu Hu Xiaoping Tang Weiping Cai Source Type: research